New York, NY & Bethesda, MD — November 20, 2020 — Precision Medicine Group (PMG) and Blackstone (NYSE: BX) today announced that PMG, a leading next-generation provider of drug development and commercialization services, has completed a major investment and recapitalization led by funds managed by Blackstone (“Blackstone”). The investment includes significant participation from Precision’s co-founders, Ethan Leder and Mark Clein, as well as current shareholders Berkshire Partners, TPG Growth, Oak HC/FT, and Vida Ventures.